<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937612</url>
  </required_header>
  <id_info>
    <org_study_id>CGHN-0801</org_study_id>
    <nct_id>NCT00937612</nct_id>
  </id_info>
  <brief_title>Postoperative Concurrent Chemoradiation for Head and Neck Cancer With Multiple Minor Risk</brief_title>
  <official_title>A Phase II Trial of Postoperative Concurrent Chemoradiation for Head and Neck Squamous Cell Carcinoma Patients With Multiple Risk Factors of Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the treatment outcome of postoperative concurrent&#xD;
      chemoradiation for head and neck squamous cell carcinoma with multiple minor risks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, postoperative chemoradiation is recommended for head and neck squamous cell&#xD;
      carcinoma with some poor prognostic feature, such as extracapsular spread of metastatic lymph&#xD;
      node, or positive resection margin. Other patients may receive postoperative radiotherapy&#xD;
      only, if they have other risk factors. In our previous study, if there are 3 or more &quot;minor&quot;&#xD;
      risk factors, the 3-year recurrence rate was 55%. This outcome was far inferior to patients&#xD;
      who had minor risk factors less than 3. Thus, we believe that current postoperative&#xD;
      radiotherapy is insufficient for patients with multiple minor risks. A clinical trial should&#xD;
      be raised to help these patients. However, the patient number of this group is not enough for&#xD;
      large scale, phase 3 trial. So we arranged this phase II trial of postoperative&#xD;
      chemoradiation to test and prospectively observe the treatment outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study group showed better results. Poor Accrual.&#xD;
  </why_stopped>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective cohort</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Any kind of cancer recurrence, measured by physical examination or image study. Pathologic confirmation is recommended.</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <arm_group>
    <arm_group_label>concurrent chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who has 3 or more minor risk factors of recurrence, and will receive postoperative chemoradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin</description>
    <arm_group_label>concurrent chemoradiation</arm_group_label>
    <other_name>CGHN 3R trial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary squamous cell carcinoma of head and neck, after tumor excision and neck&#xD;
             dissection, pathology has confirmed three or more of the following adverse prognostic&#xD;
             factors, including:&#xD;
&#xD;
               1. Marginale surgery but a safe distance from the residual tumor ≦ 4mm.&#xD;
&#xD;
               2. The tumor is located in the hard palate or the retromolar region.&#xD;
&#xD;
               3. Poorly differentiated cell type.&#xD;
&#xD;
               4. Tumor invasion to the nerve.&#xD;
&#xD;
               5. Tumor invasion to lymphatic vessels.&#xD;
&#xD;
               6. Tumor invasion to the small blood vessels.&#xD;
&#xD;
               7. Tumor invasion to the bone.&#xD;
&#xD;
               8. Tumor invasion to the skin.&#xD;
&#xD;
               9. Depth of tumor invasion ≧ 10mm.&#xD;
&#xD;
              10. Occurred in single lymph node metastasis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No or presence of adverse prognostic factor but less than 2.&#xD;
&#xD;
          -  Presence of either one conditions listed here: positive resection margin, resection&#xD;
             margin negative but less than 1 mm, pathologic N2 or N2, or presence of nodal&#xD;
             metastasis with extracapsular spreading.&#xD;
&#xD;
          -  ECOG performance status &gt; 2.&#xD;
&#xD;
          -  Previous cancer history (except basal cell or squamous cell skin cancer) or other&#xD;
             synchronous malignant disease.&#xD;
&#xD;
          -  Women during pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang-Hsing Fan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Keelung branch</name>
      <address>
        <city>Keelung</city>
        <zip>222</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou Branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Radiation Therapy, Chang Gung Memorial Hospital, Linkou branch</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>July 9, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>February 6, 2017</last_update_submitted>
  <last_update_submitted_qc>February 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Kang-Hsing Fan</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Radiotherapy, Adjuvant</keyword>
  <keyword>Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

